研究者詳細 - 那須　保友

論文 - 那須　保友

分割表示 612 件中 501 - 520 件目／全件表示 >>

前立腺癌発生率におけるテストステロンの影響に関する疫学的検討 : 元ハンセン病患者を検診対象として(第93回日本泌尿器科学会総会)

大和豊子, 雑賀隆史, 黒瀬恭平, 那須保友, 津島知靖, 公文裕巳

日本泌尿器科学会雑誌 96 ( 2 ) 165 - 165 2005年

精巣腫瘍に対する後腹膜リンパ節郭清術の検討(第93回日本泌尿器科学会総会)

津島知靖, 雑賀隆史, 枝村康平, 村上貴典, 小泉文人, 小林知子, 真鍋大輔, 江原伸, 賀来春紀, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 96 ( 2 ) 270 - 270 2005年

^<125>Iシード線源による前立腺癌永久刺入密封小線源治療(第93回日本泌尿器科学会総会)

江原伸, 真鍋大輔, 能勢宏幸, 枝村康平, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 96 ( 2 ) 426 - 426 2005年

Long-term consequence of renal function following nephrectomy for renal cell cancer 査読

Y Shirasaki, T Tsushima, Y Nasu, H Kumon

INTERNATIONAL JOURNAL OF UROLOGY 11 ( 9 ) 704 - 708 2004年9月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BLACKWELL PUBLISHING ASIA

Aim: A retrospective analysis was performed involving patients who had undergone radical nephrectomy for renal cell cancer to determine the long-term outcome of this surgery on renal status.
Materials and Methods Between 1977 and 2001, 172 patients having undergone radical nephrectomy for renal cell cancer were followed for a period of more than one year at the Department of Urology Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. The preoperative and postoperative serum creatinine values of these individuals were reviewed. Long-term effects of radical nephrectomy on renal function and factors influencing postoperative renal dysfunction were analyzed.
Results: Six (3.5%) of the 172 individuals progressed to hemodialysis. Eleven (6.4%) patients displayed serum creatinine values of greater than or equal to1.6 mg/dL. The remaining 155 patients (90.1%) demonstrated postoperative serum creatinine values of <1.6 mg/dL. The present study suggests that aging, a high degree of proteinuria, hypertension and diabetes mellitus were the predominant risk factors for renal deterioration following nephrectomy.
Conclusions: We have primarily selected radical nephrectomy for cases exhibiting smaller renal tumors with a normal contralateral kidney. We encourage nephron-sparing surgery where possible in patients displaying risk factors, including a high degree of proteinuria, hypertension, or diabetes mellitus.

Web of Science

researchmap

腎癌に対するCTガイド下経皮的ラジオ波治療(Radiofrequency Ablation) 12例の臨床的検討

小林知子, 眞鍋大輔, 江原伸, 雑賀隆史, 那須保友, 公文裕巳, 生口俊浩, 金澤右, 日下信行, 津島知靖

日本癌治療学会誌 39 ( 2 ) 929 - 929 2004年9月

Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma 査読

H Kaku, S Ito, S Ebara, M Ouchida, Y Nasu, T Tsushima, H Kumon, K Shimizu

UROLOGY 64 ( 1 ) 176 - 181 2004年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE INC

Objectives. To report our development of a new application of the inter-AN long polymerase chain reaction (PCR) for genomic scanning to screen for tumor-specific alterations in tumor DNA. Using this method, we detected a rearranged chromosomal region in renal cell carcinomas (RCCs). We then examined tumor-specific allelic loss in this region using microsatellite markers and determined whether a relationship was present between this allelic loss and the clinicopathologic features of the patients.
Methods. The inter-Alu long PCR genomic scan method was performed using RCC DNA samples and primers specific for a minor subset of the human repeat sequence Alu. We analyzed DNA samples from 42 pairs of matched normal and nonpapillary RCC tissues with seven microsatellite markers.
Results. The inter-Alu long PCR genomic scan method revealed an altered DNA region on chromosome 14q24-31, which is the location of several putative tumor suppressor genes. At least one of seven microsatellite markers on chromosome 14q24-31 showed loss of heterozygosity in 23 (54.8%) of 42 informative cases of RCC. The prevalent loss region was confined to a 2-Mb region around D14S67. We found a positive correlation between the presence of the loss of heterozygosity on 14q24-31 and tumor stage (P < 0.05). We also found that cases with allelic loss at 14q24-31 had a poor prognosis (P = 0.045).
Conclusions. Our inter-Alu long PCR genomic scan method is a powerful method for the screening of DNA alterations, and our data suggest that the chromosome 14q24-31 region contains likely tumor suppressor genes associated with the progression of RCC. (C) 2004 Elsevier Inc.

DOI： 10.1016/j.urology.2004.03.015

Web of Science

researchmap

Effects of conadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer 査読

Y Miyaji, T Saika, Y Yamamoto, N Kusaka, R Arata, S Ebara, Y Nasu, T Tsushima, H Kumon

UROLOGY 64 ( 1 ) 128 - 131 2004年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE INC

Objectives. To better understand bone metabolism and predict bone loss in treatment using gonadotropin-releasing hormone agonist for patients with prostate cancer.
Methods. The changes in bone mineral density and blood levels of bone metabolism markers and the level of pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen, a specific marker of bone resorption, and carboxy-terminal pro-peptide of human type I procollagen, a specific marker of bone formation, were examined in 27 consecutive patients with prostate cancer without bone metastasis.
Results. After 2 years of gonadotropin-releasing hormone treatment, the bone mineral density was significantly lower (median 0.937 g/cm(2)) than before treatment. Pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen began to increase significantly 6 months after the start of treatment (3.0 to 8.3 ng/mL, median 4.6, at baseline versus 3.4 to 8.2 ng/mL, median 5.2, after 6 months). Carboxy-terminal pro-peptide of human type I procollagen began to show a significant rise I year after the start of treatment (from 72.8 to 221.5 ng/mL, median 102.0, at baseline to 82.7 to 293.4 ng/mL, median 132.0, at I year).
Conclusions. Functional coupling between bone resorption and formation was noted, and a decrease in bone mass, even in men, owing to androgen deficiency, was biochemically demonstrated. Fluctuations in these two bone metabolism markers preceded the decrease of bone mineral density. Therefore, these markers might be a predictor of bone loss. (C) 2004 Elsevier Inc.

DOI： 10.1016/j.urology.2004.03.012

Web of Science

researchmap

Kidney function after nephrectomy for renal cell carcinoma 査読

Y Shirasaki, T Tsushima, T Saika, Y Nasu, H Kumon

UROLOGY 64 ( 1 ) 43 - 47 2004年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE INC

Objectives. To evaluate the function of the remaining kidney after nephrectomy for renal cell cancer by technetium-99m-mercaptoacetyltriglycine (Tc-99m-MAG3) renal scintigraphy.
Methods. We evaluated 30 consecutive patients who were undergoing unilateral radical nephrectomy by Tc-99m-MAG3 scintigraphy. All patients underwent three consecutive 99mTc-MAG3 scintigraphy studies. The first study was performed before nephrectomy, the second 1 month after surgery, and the third 1 year after surgery. At these times, the serum creatinine levels were also evaluated.
Results. The mean preoperative MAG3 clearance of the remaining kidney of the 30 patients was 155.4 mL/min/1.73 m(2). The mean MAG3 clearance of the remaining kidney had increased to 209.2 mL/min/1.73 m(2) by I month after nephrectomy, and the average percentage increase was 39.5%. After 1 year, it had increased to 211.3 mL/min/1.73 m(2), with a 40.5% average percentage increase. The preoperative MAG3 clearance of the remaining kidney was inversely correlated with the percentage of increase in MAG3 clearance of the remaining kidney. Abnormal serum creatinine levels (greater than 1.3 mg/dL) were more common after nephrectomy, occurring in 6 patients at 1 month and in 5 patients at 1 year postoperatively. In all 6 patients with elevated creatinine levels, the preoperative MAG3 clearance of the remaining kidney was less than 150 mL/min/1.73 m(2).
Conclusions. Adaptive hyperfunction occurs soon after nephrectomy that is not associated with age or sex and continues for at least 1 year. A greater compensatory response is produced in patients with more severe renal deterioration. Using (99)mTc-MAG3 scintigraphy, we may be able to predict postoperative renal function. (C) 2004 Elsevier Inc.

DOI： 10.1016/j.urology.2004.02.039

Web of Science

researchmap

Comparative study of ureteral stripping versus open ureterectomy for nephroureterectomy in patients with transitional carcinoma of the renal pelvis 査読

T Saika, J Nishiguchi, T Tsushima, Y Nasu, A Nagai, Y Miyaji, Y Maki, T Akaeda, M Saegusa, H Kumon

UROLOGY 63 ( 5 ) 848 - 852 2004年5月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE INC

Objectives. To evaluate the clinical outcome of nephroureterectomy with endoscopically assisted transurethral ureteral stripping for transitional cell carcinoma of the renal pelvis in a comparative study.
Methods. Sixty patients with localized renal pelvic cancer were enrolled in a prospective comparative nonrandomized study. Of these, 28 patients underwent nephroureterectomy with endoscopically assisted transurethral ureteral stripping and 32 underwent conventional nephroureterectomy with a bladder cuff. Both short-term and long-term results were analyzed in this series.
Results. The operating time for patients with ureteral stripping was significantly shorter than for those with a standard two-incision nephroureterectomy (median 183 versus 250 minutes, P = 0.0231), and the amount of blood loss was significantly less (median 150 versus 390 mL, P = 0.0002). Intravesical recurrence was detected in 10 (35.7%) of the 28 patients with ureteral stripping, and the 1-year and 3-year recurrence-free rate was 68.0% and 57.7%, respectively. Seven patients treated by the standard two-incision nephroureterectomy (21.9%) experienced intravesical recurrence, with a 1-year and 3-year recurrence-free rate of 96.8% and 75.0%, respectively. The recurrence rate was significantly greater in the group with ureteral stripping (P = 0.0287).
Conclusions. Compared with conventional nephroureterectomy with a bladder cuff, nephroureterectomy with transurethral stripping is a minimally invasive procedure with a shorter operating time and less blood loss, but a statistically significantly greater intravesical recurrence rate. Greater consideration should be taken before selecting this procedure. (C) 2004 Elsevier Inc.

DOI： 10.1016/j.urology.2003.12.003

Web of Science

researchmap

Analysis of retrograde ejaculation using color Doppler ultrasonography before and after transurethral collagen injection

Nagai A, Nasu Y, Watanabe M, Tsugawa M, Iguchi H, Kumon H

International Journal of Impotence Research 16 456 - 458 2004年

Ureteroscopy using a detachable access sheath

Abarazua F, Monden K, Nagai A, Nasu Y, Kumon H

Acta Med. Okayama 58 ( 4 ) 215 - 216 2004年

記述言語：英語掲載種別：研究論文（大学，研究機関等紀要）出版者・発行元：Okayama University Medical School

<p>Ureteroscopy has evolved in many aspects, particularly in the flexibility and size of ureteroscopes. We have developed a new detachable access sheath to make ureteroscopic procedures more straight-forward and to reduce possible damage to delicate instruments used in the procedure.</p>

DOI： 10.18926/AMO/32084

CiNii Article

CiNii Books

researchmap

Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma

Kurose K, Sakaguchi M, Nasu Y, Ebara S, Kaku H, Kariyama R, Arao Y, Miyazaki M, Tsushima T, Namba M, Kumon H, Huh N

J Urol 171 ( 3 ) 1314 - 1318 2004年

Dynamin-2 regulates oxidized low-density lipoprotein-induced apoptosis of vascular smooth muscle cell.

Kashiwakura Y, Watanabe M, Kusumi N, Sumiyoshi K, Nasu Y, Yamada H, Sawamura T, Kumon H, Takei K, Daida H

Circulation 110 ( 21 ) 3329 - 3334 2004年

OP4-085 99mTc-MAG3腎シンチグラフィーによる腎摘後腎機能障害の予測(一般演題(口演))

白崎義範, 那須保友, 津島知靖, 公文裕巳

日本泌尿器科学会雑誌 95 ( 2 ) 427 - 427 2004年

PP3-058 岡山大学において最近18年間に経験した上部尿路腫瘍105例の臨床的検討(一般演題(ポスター))

賀来春紀, 小林知子, 黒瀬恭平, 日下信行, 江原伸, 妹尾孝司, 雑賀隆史, 那須保友, 津島知靖, 公文裕巳

日本泌尿器科学会雑誌 95 ( 2 ) 488 - 488 2004年

The quality of life in patients with bladder cancer after cystectomy

Ryoji Arata, Tomoyasu Tsushima, Takashi Saika, Yasutomo Nasu, Hiromi Kumon, Tadashi Oeda, Yoshiyuki Miyaji, Ayano Ishii, Hitoshi Takamoto

Nishinihon Journal of Urology 66 ( 4 ) 279 - 290 2004年

記述言語：日本語掲載種別：研究論文（国際会議プロシーディングス）

A survey carried out by means of questionnaires was conducted to assess the impact of different forms of urinary diversion on the quality of life (QOL) in patients with bladder cancer. First, a QOL survey using self-administered questionnaires was carried out on 330 patients who were followed up for more than 3 months after cystectomy at the Okayama University Hospital and its affiliated hospitals. QOL assessment was performed using EORTC QLQ-C30, supplemented with detailed questionnaires about sexual function, voiding function, continence and patient's satisfaction. Among these 330 patients, 80 had an orthotopic urinary reservoir (OUR), 27 had a continent urinary reservoir (CUR) and 223 had a urostomy. Based on the answes to these questionnaires, there was little difference in the QOL score among the three groups. However, as regards satisfaction with the methods of urinary diversion, patients in the OUR group expressed better satisfaction than those in the other two groups. Second, a survey based on the same questionnaires was performed to assess the changes in the QOL of 57 patients observed prospectively from pre-surgery to one year post-surgery. Two kinds of urinary diversion were compared: 26 patients received OUR and 31 patients received urostomy. In most areas, the QOL returned to the prior level within six months after surgery. However, patients were restricted as regards their sexual function. Concerning voiding condition and continence in the OUR group, the score did not return to the prior level within one year. After one year post-surgery, no difference was recognized with regard to any of the items between the two groups.

Scopus

researchmap

Anterior urethral recurrence of superficial bladder cancer: Its clinical significance 査読

T Saika, T Tsushima, Y Nasu, R Arata, H Kaku, N Akebi, N Kusaka, H Kumon

ACTA MEDICA OKAYAMA 57 ( 6 ) 293 - 297 2003年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：OKAYAMA UNIV MED SCHOOL

The aim of this study was to reveal the clinical features of anterior urethral recurrence in patients with superficial bladder cancer, and to determine the appropriate treatment. Three hundred and three patients with superficial bladder cancer, who were newly diagnosed and initially treated conservatively in our hospital between 1965 and 1990, were followed for at least 5 years and their clinical outcomes were analyzed. Clinical factors, including anterior urethral recurrence, were evaluated statistically regarding tumor progression. Eight patients (2.6%) had anterior urethral recurrence following superficial bladder cancer. Twenty-four patients (7.9%) had tumor progression and 149 (49.2%) had tumor recurrence. In a multivariate analysis using a logistic model, anterior urethral recurrence was the most important factor, followed by histological grade. Four of 5 patients who were treated for anterior urethral recurrent tumors by transurethral resection showed progression and died of the cancer within one year. Two of the remaining three patients who underwent radical cysto-urethrectomy at the time of anterior urethral recurrence survived. Anterior urethral recurrence following superficial bladder cancer is a predictor for rapid subsequent malignant progression. Once there is anterior urethral recurrence, radical intensive therapy, including radical cysto-urethrectomy, should be carried out immediately.

Web of Science

researchmap

NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer 査読

Tetsuya Nakada, Yuji Noguchi, Shuichiro Satoh, Toshiro Ono, Takashi Saika, Takushi Kurashige, Sacha Gnjatic, Gerd Ritter, Yao-Tseng Chen, Elisabeth Stockert, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old, Eiichi Nakayama

Cancer Immunity 3 1 - 12 2003年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Academy of Cancer Immunology

NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.

Scopus

PubMed

researchmap

Laparoscopic removal of mullerian structures and orchiopexy for persistent mullerian duct syndrom

Shirasaki Y, Nagai A, Nasu Y, Iguchi H, Kumon H

Urology 62 ( 6 ) 1121 2003年

前立腺癌に対する自殺遺伝子治療臨床研究の経過報告

江原伸, 那須保友, 津島知靖, 公文裕, Thompson Timothy

日本泌尿器科学会雑誌 94 ( 2 ) 387 - 387 2003年

　前のページ - 次のページ　

<那須 保友>

論文 - 那須 保友

<那須　保友>

論文 - 那須　保友